pI: 8.6541 |
Length (AA): 770 |
MW (Da): 84900 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
34 | 684 | 4r7y (A) | 8 | 1957 | 38.00 | 0 | 1 | 1.12405 | 0.52 |
34 | 686 | 4fdg (B) | 8 | 596 | 33.00 | 0 | 1 | 1.01315 | 1.3 |
262 | 682 | 3f8t (A) | 108 | 482 | 32.00 | 0 | 1 | 0.685353 | 0.22 |
606 | 757 | 5cwm (A) | 29 | 190 | 31.00 | 0.11 | 0.85 | 0.502003 | -0.39 |
622 | 727 | 5cwl (A) | 73 | 178 | 30.00 | 0.92 | 0.98 | 0.482262 | -0.76 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127979)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G07690 | minichromosome maintenance protein 5 |
Babesia bovis | BBOV_IV010040 | DNA replication licensing factor MCM5, putative |
Brugia malayi | Bm1_24480 | DNA replication licensing factor MCM5 |
Candida albicans | CaO19.5487 | part of ARS replication initiation complex |
Candida albicans | CaO19.12942 | part of ARS replication initiation complex |
Caenorhabditis elegans | CELE_R10E4.4 | Protein MCM-5 |
Cryptosporidium hominis | Chro.70329 | DNA replication licensing factor mcm5 |
Cryptosporidium parvum | cgd7_2920 | DNA replication licensing factor MCM5 like AAA+ ATpase |
Dictyostelium discoideum | DDB_G0292958 | MCM family protein |
Drosophila melanogaster | Dmel_CG4082 | Minichromosome maintenance 5 |
Entamoeba histolytica | EHI_069980 | DNA replication licensing factor |
Giardia lamblia | GL50803_89112 | MCM5 |
Homo sapiens | ENSG00000100297 | minichromosome maintenance complex component 5 |
Leishmania braziliensis | LbrM.24.0920 | minchromosome maintenance (MCM) complex subunit, putative |
Leishmania donovani | LdBPK_240930.1 | minchromosome maintenance (MCM) complex subunit, putative |
Leishmania infantum | LinJ.24.0930 | minchromosome maintenance (MCM) complex subunit, putative |
Leishmania major | LmjF.24.0910 | minchromosome maintenance (MCM) complex subunit, putative |
Leishmania mexicana | LmxM.24.0910 | minchromosome maintenance (MCM) complex subunit, putative |
Loa Loa (eye worm) | LOAG_11821 | DNA replication licensing factor MCM5 |
Loa Loa (eye worm) | LOAG_14825 | hypothetical protein |
Mus musculus | ENSMUSG00000005410 | minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) |
Neospora caninum | NCLIV_018520 | DNA replication licensing factor, putative |
Oryza sativa | 4331016 | Os02g0797400 |
Plasmodium berghei | PBANKA_0610200 | DNA replication licensing factor MCM5, putative |
Plasmodium falciparum | PF3D7_1211700 | DNA replication licensing factor MCM5, putative |
Plasmodium knowlesi | PKNH_1311800 | DNA replication licensing factor MCM5, putative |
Plasmodium vivax | PVX_084615 | DNA replication licensing factor MCM5, putative |
Plasmodium yoelii | PY04668 | DNA replication licensing factor MCM5 |
Saccharomyces cerevisiae | YLR274W | MCM DNA helicase complex subunit MCM5 |
Schistosoma japonicum | Sjp_0017340 | ko:K02209 minichromosome maintenance protein 5 (cell division control protein, putative |
Schistosoma japonicum | Sjp_0096310 | DNA replication licensing factor mcm5-B, putative |
Schistosoma japonicum | Sjp_0017350 | ko:K02209 minichromosome maintenance protein 5 (cell division control protein, putative |
Schistosoma mansoni | Smp_143490 | DNA replication licensing factor MCM5 |
Schmidtea mediterranea | mk4.039056.00 | |
Schmidtea mediterranea | mk4.003558.01 | MCM5 |
Schmidtea mediterranea | mk4.003043.02 | |
Schmidtea mediterranea | mk4.032990.00 | |
Trypanosoma brucei gambiense | Tbg972.11.6280 | minichromosome maintenance (MCM) complex subunit, putative,DNA replication licensing factor, putative |
Trypanosoma brucei | Tb927.11.5570 | DNA replication licensing factor MCM5 |
Trypanosoma cruzi | TcCLB.508647.140 | DNA replication licensing factor MCM5, putative |
Toxoplasma gondii | TGME49_243920 | DNA replication licensing factor MCM5, putative |
Theileria parva | TP01_0722 | DNA replication licensing factor MCM5, putative |
Trichomonas vaginalis | TVAG_484360 | DNA replication licensing factor MCM5, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.3270 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.3270 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.3270 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.02.3270 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_R10E4.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_R10E4.4 | Caenorhabditis elegans | sterile | wormbase |
YLR274W | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_243920 | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.